Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 5, 2009

Ortho Biotech Joins Forces with NCI to Test Firm's Immunotherapy in Cancer

  • Ortho Biotech Oncology Research & Development entered into a five-year CRADA with the NCI to research and develop cell therapies for cancer. The company will work with Steven A. Rosenberg, M.D., Ph.D., chief, surgery branch.

    Ortho Biotech’s has developed an adoptive immunotherapy approach that uses tumor antigens and other materials to stimulate T cells from a patient's blood to become cytotoxic T lymphocytes, which recognize and attack tumor cells.

    Under the CRADA, Dr. Rosenberg's lab will conduct a clinical trial in melanoma patients using Ortho’s adoptive immunotherapy. This is expected to begin toward the end of the year. The other part of the CRADA will focus on a T-cell receptor (TCR) research program.

    Related News

    Systems Medicine Executes CRADA with NCI for Treatments Targeting the IGF Pathway (Aug. 22, 2007)
    SRI’s Oncology Candidate Wins Development Support from NCI (June 20, 2007)
    EvoGenix and NIH Team-up to Develop Antibody Therapies Against PAMP (Nov. 2, 2006)
    Millennium and Ortho Biotech Will Co-Promote Velcade in the U.S. (Oct. 26, 2006)

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »